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Background: Chronic angina is a profoundly symptomatic disease. We evaluated the relationship between angina
frequency and health utility.
Methods: We used data from stable angina patients reporting ≥3 attacks/week enrolled in the Efficacy of
Ranolazine in Chronic Angina (ERICA) trial. Angina frequency was classified using the Seattle Angina Questionnaire
angina frequency (SAQAF) domain into no (100); monthly (61-99); weekly (31-60); and daily (0-30) angina. EuroQol
(EQ)-5D health utility scores were derived from SAQ data using two mapping equations. Median EQ-5D utility scores
for each SAQAF classification after the 6-week trial period were calculated (reported as: Equation 1/Equation 2).
Changes in EQ-5D utility scores from baseline to end-of-trial for patients achieving and not achieving a ≥20-point
improvement in SAQAF score and improving and not improving ≥1 SAQAF classification were compared.
Results: Median EQ-5D utility scores (n = 548) were 0.68/0.60. Compared to patients reporting no angina symptoms
(n = 28; 0.89/0.87) patients reporting monthly (n = 188; 0.80/0.76), weekly (n = 283; 0.72/0.65) and daily (n = 49; 0.65/0.54)
symptoms had poorer health utility (p < 0.001 for both equations). Patients improving ≥1SAQAF classification
(n = 254/541, 47%) experienced a median 0.05/0.07 greater improvement in EQ-5D health utility compared to
those not improving ≥1 classification (p < 0.001 for both equations). Patients improving ≥20-points on the SAQAF
(n = 355/541, 66%) experienced a median 0.06/0.07 greater improvement in health utility compared to those not
achieving a ≥20-point improvement (p < 0.001 for both).
Conclusions: Chronic angina patient health utility decreases as angina frequency increases. Patients reporting
clinically important improvement in angina frequency experience a tangible improvement in health utility.
Clinical trial registration: NCT00091429
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It is estimated that nearly 8 million people in the United
States (US) suffer from chronic stable angina [1]. Previous
studies have demonstrated chronic stable angina has a sig-
nificant negative impact on health-related quality-of-life
(HrQoL) due to the bodily pain, psychological distress,
impaired functioning, activity restriction and inability to
care for oneself that is common to the disease [2].
The Seattle Angina Questionnaire (SAQ) [3] is a cor-
onary disease-specific patient reported outcome measure* Correspondence: Craig.Coleman@hhchealth.org
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unless otherwise stated.(PROM) that has been included as a key endpoint in nu-
merous clinical trials of stable coronary disease [4-9].
Some of these trials have published analyses evaluating
morbidity, mortality and healthcare utilization across
different frequencies of angina attacks; often categorizing
patients as having no, monthly, weekly or daily angina
symptoms based upon the angina frequency domain
[8-11]. These analyses provide valuable insight into the
relationship between angina frequency and event rates,
healthcare utilization and treatment costs; however, in
order to conduct a thorough cost-effectiveness analysis
using these data, an assessment of patient health utility
[values of preference for a disease state on a scale of 1.0
(perfect health) to 0.0 (death)] using matching angina
frequency groupings are required [12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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health utility values for persons with chronic stable an-
gina reporting the abovementioned frequencies of angina
attacks. In these situations, guidance from the National
Institute of Health and Care Excellence (NICE) [13] sup-
ports the use of mapping equations to translate re-
sponses from a PROM to an appropriate health utility
tool (e.g. EuroQoL [EQ]-5D) [14]. In this study, we used
two previously published mapping equations to convert
individual patient SAQ data from a randomized con-
trolled trial of chronic stable angina [4] into EQ-5D
health utility scores [15,16] to evaluate the relationship
between angina frequency and health utility.
Methods
Data used in this post-hoc analysis were from the
multi-national, double-blind, randomized, placebo-
controlled, parallel group Efficacy of Ranolazine in
Chronic Angina (ERICA) trial (clinicaltrials.gov registra-
tion: NCT00091429) [4]. The ERICA trial was approved
by the institutional review board at each participating
hospital, and each patient provided written informed
consent. ERICA evaluated the effectiveness of ranolazine
(1,000 mg twice daily) in adults with a documented his-
tory of coronary disease, at least a 3-month history of
chronic stable angina, and reporting ≥3 episodes of
angina/week during a 2-week qualification period despite
treatment with 10 mg/day of amlodipine.
The SAQ was a secondary outcome measure adminis-
tered at baseline and at the end of the 6-week double-
blind full-dose trial phase. The SAQ is a validated,
coronary disease-specific PROM comprising 19 items
that quantify 5 clinically relevant domains of health sta-
tus (angina frequency, physical limitation, angina stabil-
ity, treatment satisfaction and disease perception) each
scored on a scale of 0 to 100, with higher scores indicat-
ing better health status [3]. For this analysis, we used the
SAQ angina frequency (SAQAF) domain scores to clas-
sify patients into discrete angina frequency categories;
with a score of 100 = no; 61-99 =monthly; 31-60 = weekly;
0-30 = daily angina symptoms [9,10,17].
Two unique and independently derived mapping equa-
tions were used to translate (or cross-walk) individual
SAQ domain scores for patients in the ERICA trial to
EQ-5D-based health utility scores [15,16]. The first
equation was derived in nearly 3,000 participants of the
Alberta Provincial Project for Outcome Assessment in
Coronary Heart Disease (APPROACH) database using
linear regression within a Bayesian framework and scor-
ing the EQ-5D using the US scoring algorithm (which
ranges from −0.11 to 1.0 on a scale where 0.0 = death
and 1.0 = perfect health). The equation [EQ-5D = 0.0010*
(angina frequency domain score) – 0.0002*(angina sta-
bility domain score) + 0.0023 (disease perception domainscore) + 0.0019 * (physical limitation domain score) +
0.0004 * (treatment satisfaction domain score) + 0.4388]
uses all 5 domains of the SAQ to estimate EQ-5D health
utility scores with a mean absolute error (MAE) of 0.088
(adjusted R2 = 0.37). The second equation used patient-
level data from 5 studies of cardiac interventions, 3 of
the 5 SAQ domains along with patient demographics,
ordinary least squares linear regression methods and the
United Kingdom (UK) scoring algorithm for the EQ-5D
(which ranges from −0.594 to 1.0 on a scale where
0.0 = death and 1.0 = perfect health) to derive the following
equation: EQ-5D = 0.002*(age) - 0.009 (if male) + 0.021
(if medically managed) + 0.048 (if pre-percutaneous coron-
ary intervention (PCI)) + 0.018 (if post-PCI) + 0.073(if
pre-coronary artery bypass grafting) + 0.0036 *(physical
limitation domain score) + 0.0021* (disease perception
domain score) + 0.0015 * (angina frequency domain
score) + 0.147 to estimate EQ-5D index scores with a
MAE of 0.123 (adjusted R2 = 0.44).
Our analysis included all patients randomized in the
ERICA trial that received at least one dose of double-
blind investigational drug, had at least one subsequent
primary efficacy assessment during the double-blind trial
period and had a complete SAQ assessment at ran-
domization and at the end-of-trial.
We estimated median (along with 25%, 75% ranges)
EQ-5D health utility scores at randomization and at the
end-of-trial for each patient using the above-mentioned
mapping equations. Comparison of EQ-5D health utility
scores across the four SAQ-based angina frequency
classifications were made using end-of-trial values only
(as no subjects were classified as having no angina
symptoms and few were classified as having monthly
symptoms at baseline due to trial inclusion criteria).
We calculated change in EQ-5D health utility scores
from randomization to end-of-trial and compared these
values between subjects improving and not improving ≥1
SAQAF classification. Additionally we compared the
change EQ-5D health utility scores for subjects achieving
and not achieving a ≥20-point improvement in SAQAF
domain score; a threshold previously reported as the
minimally important clinical difference on the SAQAF
domain score [11].
Categorical data were compared using chi-squared tests.
Continuous data were compared using a Mann–Whitney U
or Kruskal-Wallis one-way analysis of variance test, where
appropriate. A p-value <0.05 was considered statistically
significant in all situations. All analyses were conducted
using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the 565 subjects randomized in the
ERICA trial have been published previously [4]. We
briefly summarize their key characteristics in Table 1.
Table 1 Demographics, baseline characteristics and medical







Age (years), mean ± SD 61.3 ± 9.0 62.0 ± 8.7






Eastern Europe 97 97
North America 3 3
Concomitant use of LANs,% 43 46






Weekly rate of NTG consumption,





SAQ score, mean ± SD




















History of unstable angina,% 98 (35) 100 (36)
History of CHF,% 145 (51) 146 (52)
NYHA functional class I 38 (13) 32 (11)
NYHA functional class II 86 (30) 99 (35)
NYHA functional class III 21 (7) 15 (5)
NYHA functional class IV 0 0
Diabetes mellitus,% 54 (19) 52 (19)
Insulin-dependent 2 (1) 11 (4)
Previous myocardial infarction,% 233 (82) 218 (78)
Previous CABG,% 34 (12) 28 (10)
Previous PCI 25 (9) 34 (12)
Intermittent claudication,% 32 (11) 39 (14)
Hypertension,% 257 (91) 246 (88)
CABG = Coronary Artery Bypass Grafting; CHF = Congestive Heart Failure;
ERICA = Efficacy of Ranolazine in Chronic Angina; LAN = long-acting nitrate;
NTG = nitroglycerin; NYHA = New York Heart Association; PCI = Percutaneous
Coronary Intervention; SAQ = Seattle Angina Questionnaire; SD = standard
deviation; SE = standard error.
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were available in 548 of the patients (97% of all random-
ized). At baseline, the total trial population reportedmedian SAQAF domain score of 40 (40, 50) with 6%,
71% and 23% reporting monthly, weekly and daily an-
gina symptoms, respectively. Median EQ-5D health util-
ity scores were 0.68 (0.64, 0.73) and 0.60 (0.55, 0.66) at
baseline based on Equation 1 and 2.
Median EQ-5D health utility scores for each of the a
priori determined SAQAF classifications at end-of-trial
are reported in Table 2. A statistically significant associ-
ation was seen between angina frequency classifications
and EQ-5D health utility scores; with more frequent an-
gina resulting in decrements in health utility (p < 0.001
for association for both Equations 1 and 2).
Patients who improved at least one SAQAF category
from baseline (n = 254/541, 47%) experienced a median
0.05/0.07 greater improvement in EQ-5D health utility
score compared to those not improving by at least
one SAQAF classification (p < 0.001 for data based
on both mapping equations) (Figure 1). Patients who
improved ≥20-points on their SAQAF domain score
from baseline (n = 355/541, 66%) experienced a median
0.06/0.07 greater improvement in EQ-5D health utility
score compared to those not achieving a ≥20-point im-
provement (p < 0.001 for both equations) (Figure 2).
Discussion
Using patient data from a randomized chronic stable an-
gina trial [4] and 2 two different mapping equations
[15,16], we have demonstrated that EQ-5D health utility
values decrease significantly with worsening angina fre-
quency categorization. The two independently derived
mapping equations used in this analysis provided similar
results; and depending on the equation used, patients
regularly experiencing angina attacks reported clinically-
relevant 0.07 (for monthly) to 0.33 (for daily) unit decre-
ments (11% to 61% relative decrements) in health utility
compared to patients reporting no angina. We also dem-
onstrated patients improving by at least one SAQAF
classification or reporting at least a 20-point improve-
ment on the SAQAF domain score (previously estimated
to signify a minimally important improvement) experi-
enced a statistically significant and clinically-relevant im-
provement in health utility score. Thus, the above data
suggests that appropriate management of stable angina
symptoms can result in important improvement in
patient HrQoL. In addition, our analysis provides the
needed health utility values for stable angina patients
with differing frequencies of angina symptoms required
to calculate quality-adjusted life-years (QALYs) in cost-
effectiveness (utility) analyses [12].
A previous analysis by the MERLIN –TIMI 36 investi-
gators [16,18] (published in abstract form only) has
also reported health utility values based upon the same
SAQAF domain score categories we used. As in ours,
this analysis demonstrated a strong and statistically
Table 2 EQ-5D health utility scores at end-of-trial stratified by Seattle Angina Questionnaire Angina Frequency Classification
based upon mapping equations 1 and 2
Mapping Equation 1# Mapping Equation 2†
SAQAF domain score N Median EQ-5D score 25%, 75% range P-Value* Median EQ-5D score 25%, 75% range P-Value*
Overall 548 0.75 0.69, 0.80 NA 0.68 0.62, 0.77 NA
No (100) 28 0.89 0.84, 0.92 Referent 0.87 0.77, 0.91 Referent
Monthly (61–99) 188 0.80 0.75, 0.85 <0.001 0.76 0.70, 0.81 <0.001
Weekly (31–60) 283 0.72 0.68, 0.76 <0.001 0.65 0.61, 0.70 <0.001
Daily (0–30) 49 0.65 0.61, 0.69 <0.001 0.54 0.52, 0.61 <0.001
EQ-5D = EuroQol 5-Dimension; N = number of patients; SAQAF = Seattle Angina Questionnaire Angina frequency.
*p < 0.001 for the overall association using a Kruskal-Wallis one-way analysis of variance test; p-values for angina frequency domain score comparisons to “no”
angina (referent) using Mann–Whitney U test.
#Mapping Equation 1 =Wijeysundera 2011 [15].
†Mapping Equation 2 = Goldsmith 2010 [16].
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quency and health utility (“no” = 0.96; “monthly” = 0.81;
“weekly” = 0.72; and “daily” = 0.65). Of note, unlike our
own analysis, the MERLIN trial elicited health utility
values by administering the EQ-5D tool to a large num-
ber of subjects (n = 5,388) 4-months after randomization.
However, since MERLIN only included patients within
48-hours of a non-ST-segment elevation acute coronary
syndrome, the reported health utility values may not fully
represent those of a stable angina population [6]. There-
fore, our analysis adds important information to current
body of literature.
The two mapping equations [15,16] we used in our
study to estimate health utility values had some im-
portant differences worthy of discussion. While bothFigure 1 Median Change in EQ-5D Health Utility Score From Baseline
Score Class Responders and Non-Responders. This figure presents box-
baseline for SAQAF class responders (improving by at least one classification
For each plot, the central box spans the first quartile to the third quartile (or
the median value for the subjects. The whiskers above and below the
Equation 1 =Wijeysundera 2011 [15]. ±Mapping Equation 2 = Goldsmith 201equations used SAQ domain scores to estimate EQ-5D
health utility values; the equation by Wijeysundera and
colleagues utilized all 5 SAQ domains, while the equation
by Goldsmith and colleagues used only 3 (angina fre-
quency, physical limitation and disease perception). Next,
the equation by Goldsmith included demographic vari-
ables such as age, gender and use of PCI and CABG
along with SAQ domains. By using this additional infor-
mation, they were able to develop an equation that
explained/predicted a greater proportion of the total vari-
ation in EQ-5D health utility scores evidenced by its
higher adjusted R2 compared to Wijeysundera. However,
a potential downside of including this data is that re-
searchers wanting to utilize a mapping equation may
not have access to some or all of these demographicfor Seattle Angina Questionnaire Angina Frequency Domain
and-whisker plots for the change in EQ-5D health utility score from
) and non-responders based upon data from both mapping equations.
the interquartile range), with the black line dividing the box depicting
box show the minimum and maximum subject values. *Mapping
0 [16]. †p-values calculated using Mann–Whitney U tests.
Figure 2 Median Change in EQ-5D Health Utility Score From Baseline for Seattle Angina Questionnaire Angina Frequency Domain
Score 20-Point Responders and Non-Responders. This figure presents box-and-whisker plots for the change in EQ-5D health utility score from
baseline for SAQAF 20-point responders and non-responders based upon data from both mapping equations. For each plot, the central box
spans the first quartile to the third quartile (or the interquartile range), with the black line dividing the box depicting the median value for the
subjects. The whiskers above and below the box show the minimum and maximum subject values. EQ-5D = EuroQol 5-Dimension; N = number of
patients. *Mapping Equation 1 =Wijeysundera 2011 [15]. ±Mapping Equation 2 = Goldsmith 2010 [16]. †p-values calculated using Mann–Whitney
U tests.
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used the US algorithm to score the EQ-5D, Goldsmith
used the UK scoring algorithm. Given this is a multi-
national trial, neither equation is preferable; however, it is
important to note that the scoring algorithms result in
different potential ranges of values (−0.11 to 1.0 for the
US and −0.594 to 1.0 for the UK equation) [14,15]. It
is likely that each of the above-mentioned differences
between the two mapping equations contributed to the
differing EQ-5D health utility estimates arrived at by the
two equations in our study.
There are some limitations to our analysis worth
further discussion. First, since the SAQ domain scores re-
quired for mapping came from a single, moderately-sized
randomized trial [4] that initially enrolled patients experi-
encing a relatively high frequency of angina and then
treated these patients with an effective antianginal (ie,
ranolazine), few patients finished the trial in the “no” or
“daily” angina frequency categories. As a result, our esti-
mates of health utility in these categories are associated
with greater variance than the estimates in the ”monthly”
and “weekly” groups with larger sample sizes. Next, as
highlighted in the NICE guidance document [13], map-
ping is “at best, a second-best solution” to the direct col-
lection of EQ-5D health utility values. However, in order
to conduct a thorough cost-effectiveness analysis of stable
angina interventions, an assessment of patient health util-
ity using matching angina frequency groupings are re-
quired [12]. Unfortunately, there is a paucity of healthutility data for discrete angina frequency categories in pa-
tients with chronic stable angina, and the ERICA trial did
not utilize the EQ-5D or similar tool to elicit them dir-
ectly. Consequently, our data likely represents some of the
best estimates currently available. Finally, to address the
potential short-coming of using any one mapping equa-
tion, we used multiple equations in this analysis to esti-
mate a range of potential values.Conclusion
Chronic angina patient health utility values decrease as
angina frequency increases. Our health utility estimates for
stable angina patients stratified by angina frequency may
be useful for conducting cost-effectiveness analyses in the
future. Patients reporting at least a clinically important im-
provement in angina frequency experience a tangible im-
provement in health utility. Due to the strong relationship
between these two outcome measures, future studies of
chronic stable angina interventions should include health
utility measures to aid in health economic evaluation.Consent
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